These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30929185)

  • 1. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
    Cheng AYY; Patel DK; Reid TS; Wyne K
    Adv Ther; 2019 May; 36(5):1018-1030. PubMed ID: 30929185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of basal insulins: A review.
    Vargas-Uricoechea H; Aschner P
    Diabetes Metab Syndr; 2021; 15(6):102318. PubMed ID: 34695771
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

  • 8. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosynthetic Human Insulin and Insulin Analogs.
    Rodbard HW; Rodbard D
    Am J Ther; 2020; 27(1):e42-e51. PubMed ID: 31876563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV; Paschos P; Karagiannis T; Katsoula A; Athanasiadou E; Kitsios K; Bekiari E; Matthews DR; Tsapas A
    Ann Intern Med; 2018 Aug; 169(3):165-174. PubMed ID: 29987326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
    Muñoz Torres M
    Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
    Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
    Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
    Kerlan V; Gouet D; Marre M; Renard É
    Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.
    Mehta R; Goldenberg R; Katselnik D; Kuritzky L
    Ann Med; 2021 Dec; 53(1):998-1009. PubMed ID: 34165382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of basal insulins.
    Barnett AH
    Diabet Med; 2003 Nov; 20(11):873-85. PubMed ID: 14632712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.